← All Disc Medicine, INC filings

Disc Medicine, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
IRON
Disc Medicine, INC
10-K: Disc Medicine Faces Bitopertin Setback, Boosts Cash Reserves
Disc Medicine received a Complete Response Letter from the FDA for bitopertin's accelerated approval in EPP and XLP, while reporting increased net losses and a strong cash position.
NASDAQ
IRON
Disc Medicine, INC
10-K: Disc Medicine's 10-K Filing Reveals Plans for Accelerated Approval of Bitopertin and Continued Clinical Development
Disc Medicine's 10-K filing highlights the company's focus on hematologic diseases, plans for bitopertin's accelerated approval, and ongoing clinical trials for other product candidates.
NASDAQ
IRON
Disc Medicine, INC
10-K: Disc Medicine Reports 2023 Financial Results and Provides Clinical Pipeline Update
Disc Medicine, a clinical-stage biopharmaceutical company, released its 2023 financial results and provided an update on its clinical pipeline, highlighting progress in its hematologic disease programs.